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Abstract. IT providers offering services based on genetic data face serious 
challenges in managing health data in compliance with the General Data Protection 
Regulation (GDPR). Based on a literature research and our experiences, an overview 
of GDPR compliant processing of sensitive data is given. The GDPR requirements 
for processing sensitive data were specified for a use case concerning a service 
provider of a pharmacogenomic decision support system. Start-ups who want to 
enter into the health market also have to comply with the Medical Device Regulation 
(MDR). The associated efforts for legal compliance constitute an impediment for 
many start-ups. We created a comprehensive overview, which aligned the 
requirements of the GDPR with the life-cycle of a medical device. This overview 
shall help start-ups to grasp and overcome the regulatory hurdles faster. 
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1. Introduction 
Pharmacogenomics (PGx) deals with genetic effects on the metabolic pathways of drugs 
[1]. Even though, clear targets are defined in guidelines [2], there is a lack of PGx testing, 
especially due to paucity of knowledge and implementation know-how. This explains 
the existence of IT service providers in this domain, offering, for example, workflows 
for PGx clinical decision support. However, such providers are facing serious challenges 
with respect to health data management, which can lead to sub-optimal service delivery. 
Here, we describe challenges posed by the General Data Protection Regulation 
(GDPR) with the aim to comprehensively guide IT providers offering services based on 
sensitive and in particular genetic/genomics data. Especially, GDPR compliant storage 
and transfer of sensitive data are central issues that will be addressed. In addition to that, 
we will also discuss implications of the Medical Device Regulation (MDR) and ways to 
integrate its requirements into an overall perspective. 
2. Methods 
Information on the GDPR and its references to genetic data was obtained with a PubMed 
research using the MeSH terms (GDPR[Title/Abstract]) AND (genomic[Title/Abstract] 
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OR genetic[Title/Abstract] OR sensitive[Title/Abstract]). The resulting articles were 
analyzed and categorized according to their relevance. We relied on PubMed rather than 
legal databases as our focus was on practical approaches to establish conformance with 
the GDPR. The analysis was enriched by considering additional challenges implied by 
the MDR and our own experiences at the intersection between research and the market. 
3. Results 
3.1. GDPR Compliant Processing of Sensitive Data 
Our PubMed research led to 17 articles, including four relevant articles for our purpose 
to provide some guidance for the practice [3–6]. Sariyar et al. [7] discuss GDPR related 
issues around different types of genetic data. They emphasize that the GDPR is 
demanding higher protection and stricter requirements for genetic data than for other 
sorts of personal data, as genetic data may contain sensitive information about the data 
subject and their blood relatives [8]. However, there are no additional data protection 
implications related to genetic data compared to other forms of sensitive data such as 
data concerning health, sexuality or sexual orientation. 
The GDPR also defines fundamental rights of the data subject (defined as 'identified 
or identifiable natural person' (Art. 4) from which data is being collected, held or 
processed). The controller, defined as 'natural or legal person (...) which (...) determines 
the purposes and means of the processing of personal data' (Art. 4), is obliged to provide 
information such as the purposes of the processing for which the personal data are 
intended as well as the legal basis for the processing (Art. 13 (1) lit c). Moreover, the 
controller is responsible for the implementation of appropriate technical and 
organizational measures to ensure data processing according to the regulation (Art. 24 
(1)). Organizational measures are, for example, the provision of explicit consent forms 
to the users, the assignment of roles for access control and the carrying out of a Data 
Protection Impact Assessment (DPIA). The technical measures include implementation 
such as authentication (Recital 57) and access control (Recital 39), encryption (Recital 
83), pseudonymization (Recital 78) etc. The stored data must be provided in a structured, 
commonly used and machine-readable format (Art. 20 (1)). As the data subject has the 
right to rectification (Art. 16), to erasure (Art. 17 (1)) and/or to restriction of processing 
(Art. 18 (1)) the data, the data controller must be able to carry out these tasks. 
Besides the data controller, the GDPR also defines the role of a data processor, 
which processes personal data on behalf of the controller (Art. 4). Processing by a 
processor is governed by a contract or other legal act that is binding on the processor 
with regard to the controller (Art. 28 (3)). From the GDPR perspective, the data processor 
is primarily responsible for applying technical measures described above. In addition to 
data controller and data processor, further roles such as data protection officer have to be 
assigned as well under certain conditions (Art. 37 (1)). 
3.2. Scenario: PGx Service in an B2B Environment 
In the following, we concretize how the regulatory requirements can be fulfilled based 
on the use case of an PGx CDSS service provided for health professionals. Four roles 
have to be differentiated in such a setting: 
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1. Patient (Data subject): the person whose personal data is being collected. 
2. Health Organization (Data controller): a laboratory or hospital performing gene 
sequencing & analysis and storing the corresponding data. 
3. Health Professional (Data processor): a physician or other professionals 
working in a health organization. 
4. Service provider (Data processor): a company offering the PGx service. 
Figure 1 shows the central processes: 1) The patient gives his explicit consent by 
signing the corresponding form provided by the health organization, 2) his blood sample 
is taken by the health professional and 3) analyzed & stored by the health organization. 
4) The related pseudonymized data is transmitted to the service provider 5), where it is 
stored. 6) During drug prescription, the drug information and the present medication of 
a patient together with its pseudonym is sent to the software provider, which infers PGx 
information. 7) This information is provided to the physician in order to ensure 8) a PGx 
safe drug therapy. Central tasks of the health organization are pseudonymization prior to 
transmission to the software provider, assigning roles, access control, and carrying out 
an DPIA. The software provider is responsible for fulfilling further requirements of the 
GDPR, e.g. providing the functionality for erasure (Art. 17 (1)), provide data in machine-
readable format (Art. 20 (1)) etc. 
 
 
Figure 1. Processes in the PGx service scenario, listing some technical and organizational measures for the 
data controller and data processor. 
3.3. Considering the MDR for an Overall Perspective 
Processing of genetic data for research purposes is mainly regulated by the GDPR. 
However, companies operating in the health sector need also to be compliant with the 
MDR and acquire a corresponding medical device certification. The associated efforts 
constitute one central reason why many start-ups shy away from entering into the market 
and prolong their time within the research environment. With the MDR, further 
requirements, such as a comprehensive quality management system (QMS) according to 
ISO 13485, have to be met. Table 1 summarizes the main regulatory requirements that 
need to be considered by a health IT service provider in each phase of its product cycle, 
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Table 1. Actions to fulfill GDPR and MDR requirements along the product life-cycle. 
 MDR GDPR 
Idea Define intended purpose. Classify product 
(MDR Annex VIII). Implement QMS 
(ISO 13485). 
Identify collected data and requirements. 
Design Consider risk management measures  
(ISO 14971). 
Consider security, privacy and compliance 
requirements. 
Development Develop the product and document the 
development process (MDR Annex II). 
Add supporting tools (Consent tracking, 
access control etc.). 
Audit Proof the conformity with the regulations. 
If necessary, audit with notified body. 
Data privacy certification (voluntary, see 
Art. 42 (3)). 
Release UDI registration (MDR Art. 29) and CE 
marking (MDR Art. 20). 
- 
PMS Surveillance and monitoring  
(MDR Art. 83 seq.). 
Ensure data security, consent tracking etc. 
4. Discussion/Conclusions 
The main goal of the GDPR is to enhance effectiveness and harmonization of data 
protection in the EU; however, deviations from it are existent in several countries. In 
Switzerland, for example, the data subjects’ rights are different and not defined in the 
corresponding Federal Act of Data Protection, but regulated by other regulations within 
the Swiss legal system, e.g. the Federal Act on Human Genetic Testing HGTA 
(abbreviated as GUMG in German). It is important to take such deviations into 
consideration, when providing services throughout Europe. For the MDR, no such 
deviations are to be expected. However, for countries like Switzerland an authorized 
representative has to be established within one of the EU 27 member states. 
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